Homology Medicines, Inc. (0T6G.L)
USD 1.94
(-2.52%)
USD 1.94
(-2.52%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 47.05 Million USD | -79.4% |
| 2022 | 228.47 Million USD | 7.91% |
| 2021 | 211.72 Million USD | -19.72% |
| 2020 | 263.73 Million USD | -15.08% |
| 2019 | 310.56 Million USD | 19.87% |
| 2018 | 259.09 Million USD | 88.39% |
| 2017 | 137.53 Million USD | 867.21% |
| 2016 | 14.21 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 124.2 Million USD | -18.46% |
| 2024 Q1 | 152.33 Million USD | -50.24% |
| 2023 Q1 | 197.88 Million USD | -13.39% |
| 2023 Q3 | 140.06 Million USD | -17.29% |
| 2023 FY | 306.11 Million USD | 33.99% |
| 2023 Q4 | 306.11 Million USD | 118.56% |
| 2023 Q2 | 169.33 Million USD | -14.42% |
| 2022 Q3 | 262.65 Million USD | -7.72% |
| 2022 Q2 | 284.6 Million USD | -8.47% |
| 2022 Q1 | 310.95 Million USD | 46.87% |
| 2022 Q4 | 228.47 Million USD | -13.01% |
| 2022 FY | 228.47 Million USD | 7.91% |
| 2021 Q3 | 230.81 Million USD | -10.85% |
| 2021 Q4 | 211.72 Million USD | -8.27% |
| 2021 FY | 211.72 Million USD | -19.72% |
| 2021 Q2 | 258.91 Million USD | 10.32% |
| 2021 Q1 | 234.69 Million USD | -11.01% |
| 2020 FY | 263.73 Million USD | -15.08% |
| 2020 Q3 | 228.36 Million USD | -11.57% |
| 2020 Q4 | 263.73 Million USD | 15.49% |
| 2020 Q2 | 258.23 Million USD | -10.58% |
| 2020 Q1 | 288.78 Million USD | -7.01% |
| 2019 Q2 | 341.15 Million USD | 46.4% |
| 2019 FY | 310.56 Million USD | 19.87% |
| 2019 Q1 | 233.02 Million USD | -10.06% |
| 2019 Q4 | 310.56 Million USD | -1.95% |
| 2019 Q3 | 316.75 Million USD | -7.15% |
| 2018 Q2 | 270.31 Million USD | 109.42% |
| 2018 FY | 259.09 Million USD | 88.39% |
| 2018 Q4 | 259.09 Million USD | -3.47% |
| 2018 Q3 | 268.39 Million USD | -0.71% |
| 2018 Q1 | 129.07 Million USD | -6.15% |
| 2017 FY | 137.53 Million USD | 867.21% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 137.53 Million USD | 0.0% |
| 2016 FY | 14.21 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.312% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 76.162% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 96.074% |
| Evolus, Inc. | 188.99 Million USD | 75.102% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 98.426% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 99.563% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 94.979% |
| uniQure N.V. | 831.68 Million USD | 94.342% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 69.52% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 71.567% |
| bluebird bio, Inc. | 619.16 Million USD | 92.4% |
| Abeona Therapeutics Inc. | 64 Million USD | 26.476% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 98.771% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 92.429% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 93.951% |
| Dynavax Technologies Corporation | 997.09 Million USD | 95.281% |
| Editas Medicine, Inc. | 499.15 Million USD | 90.573% |
| FibroGen, Inc. | 423.52 Million USD | 88.889% |
| Geron Corporation | 394.07 Million USD | 88.059% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 95.515% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.824% |
| Illumina, Inc. | 10.11 Billion USD | 99.535% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 93.97% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 15.893% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.553% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 62.607% |
| Adicet Bio, Inc. | 207.29 Million USD | 77.3% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 98.559% |
| Insmed Incorporated | 1.32 Billion USD | 96.461% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 96.383% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 98.598% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 28.365% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 96.66% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.942% |
| Waters Corporation | 4.62 Billion USD | 98.983% |
| Zoetis Inc. | 14.28 Billion USD | 99.671% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.952% |
| Biogen Inc. | 26.84 Billion USD | 99.825% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 71.536% |
| Nektar Therapeutics | 398.03 Million USD | 88.178% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 87.23% |
| Perrigo Company plc | 10.8 Billion USD | 99.565% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 92.0% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 78.851% |
| Verastem, Inc. | 149.71 Million USD | 68.57% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.793% |
| Imunon, Inc. | 21.91 Million USD | -114.695% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -66.442% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 77.134% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.858% |
| OPKO Health, Inc. | 2.01 Billion USD | 97.661% |
| Exelixis, Inc. | 2.94 Billion USD | 98.401% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 97.285% |
| TG Therapeutics, Inc. | 329.58 Million USD | 85.722% |
| Incyte Corporation | 6.78 Billion USD | 99.306% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 97.435% |